Exact Sciences (EXAS) Tops Q4 EPS by 27c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Exact Sciences (EXAS) PT Lowered to $65 at BTIG
February 20, 2025 6:47 AM ESTBTIG analyst Mark Massaro lowered the price target on Exact Sciences (NASDAQ: EXAS) to $65.00 (from $75.00) while maintaining a Buy rating.
The analyst comments "Consistent with the company's pre-announce last month, EXAS delivered a modest Q4 revenue beat, as screening and precision oncology in 2024 grew +13% and +4% Y/Y, respectively. In... More
